Table 2.

Changes in DNMT1 mobility under treatment with 5-azacytidine and TSA

Treatment	Parametera	Value for the indicated cell line
		Hep3B	U373MG	U343MG
Control	1 − y	0.4 ± 0.2	0.5 ± 0.2	0.5 ± 0.2
	τ1 (μs)	250 ± 150	250 ± 150	250 ± 150
	y	0.6 ± 0.2	0.5 ± 0.2	0.5 ± 0.2
	τ2 (ms)	10 ± 5	20 ± 15	10 ± 5
5-Azacytidine	1 − y	0.4 ± 0.2	0.7 ± 0.2	0.6 ± 0.2
	τ1 (μs)	250 ± 150	250 ± 150	250 ± 150
	y	0.6 ± 0.2	0.3 ± 0.2	0.4 ± 0.2
	τ2 (ms)	10 ± 5	8 ± 5	8 ± 5
TSA	1 − y	0.7 ± 0.2	0.7 ± 0.2	0.6 ± 0.2
	τ1 (μs)	250 ± 150	250 ± 150	150 ± 100
	y	0.3 ± 0.2	0.3 ± 0.2	0.4 ± 0.2
	τ2 (ms)	5 ± 3	8 ± 5	15 ± 10

^aτ₁ and τ₂ are the apparent diffusion times or the apparent average residence times in the nucleoplasm and the chromatin-dense domains, respectively; y is the fraction of the bound DNMT1.